ÀϺ»ÀÇ ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á ½ÃÀå º¸°í¼­ : Ä¡·á À¯Çü, ÀûÀÀÁõ, µô¸®¹ö¸® ¸ðµå, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº°(2025-2033³â)
Japan Cell and Gene Therapy Market Report by Therapy Type, Indication, Delivery Mode, End User, and Region 2025-2033
»óǰÄÚµå : 1609740
¸®¼­Ä¡»ç : IMARC Group
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 121 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,999 £Ü 4,189,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 3,999 £Ü 5,586,000
PDF & Excel (5 User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,999 £Ü 6,983,000
PDF & Excel (Corporate License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ÀϺ»ÀÇ ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á ½ÃÀåÀÇ ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 7¾ï 2,700¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº ½ÃÀåÀÌ 2033³â±îÁö 20¾ï 1,600¸¸ ´Þ·¯¿¡ ´ÞÇϸç, 2025-2033³â 12%ÀÇ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ¸¸¼ºÁúȯ ¹× À¯Àü¼º ÁúȯÀÇ Áõ°¡¿¡ ÀÇÇØ ÀÌ·¯ÇÑ ÇコÄÉ¾î °úÁ¦¿¡ ´ëóÇÒ ¼ö Àִ ÷´Ü Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁö°í ÀÖÀ¸¸ç, À̰ÍÀÌ ÁÖ·Î ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

º» ¸®Æ÷Æ®¿¡¼­ ´äº¯ÇÏ´Â ÁÖ¿ä Áú¹®

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

Á¦3Àå °³¿ä

Á¦4Àå ÀϺ»ÀÇ ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á ½ÃÀå : ¼­·Ð

Á¦5Àå ÀϺ»ÀÇ ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á ½ÃÀå ±¸µµ

Á¦6Àå ÀϺ»ÀÇ ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á ½ÃÀå : Ä¡·á À¯Çüº° ³»¿ª

Á¦7Àå ÀϺ»ÀÇ ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á ½ÃÀå : ÀûÀÀÁõº° ³»¿ª

Á¦8Àå ÀϺ»ÀÇ ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á ½ÃÀå : µô¸®¹ö¸® ¸ðµåº° ³»¿ª

Á¦9Àå ÀϺ»ÀÇ ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº° ³»¿ª

Á¦10Àå ÀϺ»ÀÇ ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á ½ÃÀå : °æÀï ±¸µµ

Á¦11Àå ÁÖ¿ä ±â¾÷ÀÇ °³¿ä

Á¦12Àå ÀϺ»ÀÇ ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á ½ÃÀå : ¾÷°è ºÐ¼®

Á¦13Àå ºÎ·Ï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Japan cell and gene therapy market size reached USD 727 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 2,016 Million by 2033, exhibiting a growth rate (CAGR) of 12% during 2025-2033. The increasing adoption of chronic and genetic diseases is propelling the demand for advanced therapies capable of addressing these healthcare challenges, which is primarily driving the market growth.

Cell and gene therapy are cutting-edge medical approaches that hold immense promise for the treatment of various diseases and conditions. In essence, cell therapy involves the transplantation or manipulation of living cells to replace or repair damaged or malfunctioning tissues within the body. This can include the use of stem cells to regenerate damaged organs or tissues. On the other hand, gene therapy focuses on modifying or correcting faulty genes responsible for causing diseases. This can be achieved by introducing, replacing, or repairing specific genes within a patient's cells. Both cell and gene therapy are at the forefront of personalized medicine, offering the potential to provide targeted, individualized treatments that can address the root causes of diseases, rather than just managing their symptoms. These innovative therapies have shown remarkable success in clinical trials and are paving the way for a new era in healthcare, with the potential to revolutionize the treatment of genetic disorders, cancer, and a range of other challenging medical conditions.

Japan Cell and Gene Therapy Market Trends:

The Japan cell and gene therapy market is rapidly emerging as a dynamic and promising sector within the country's healthcare landscape. With an aging population and a growing burden of chronic diseases, there is a heightened demand for innovative treatments that can offer long-term solutions. Cell and gene therapy have gained significant attention and investment in Japan due to their potential to address unmet medical needs. Japanese researchers and biopharmaceutical companies have been actively engaged in developing novel therapies using these cutting-edge technologies. Regulatory authorities in Japan have also taken steps to facilitate the clinical development and commercialization of cell and gene therapies, making it an attractive market for both domestic and international players. The market's growth is further fueled by collaborations between academia, industry, and healthcare providers, as well as the increasing adoption of precision medicine approaches. As a result, the Japan cell and gene therapy market is poised for continued expansion and is likely to play a pivotal role in the future of healthcare in the country.

Japan Cell and Gene Therapy Market Segmentation:

Therapy Type Insights:

Indication Insights:

Delivery Mode Insights:

End User Insights:

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

Table of Contents

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Japan Cell and Gene Therapy Market - Introduction

5 Japan Cell and Gene Therapy Market Landscape

6 Japan Cell and Gene Therapy Market - Breakup by Therapy Type

7 Japan Cell and Gene Therapy Market - Breakup by Indication

8 Japan Cell and Gene Therapy Market - Breakup by Delivery Mode

9 Japan Cell and Gene Therapy Market - Breakup by End User

10 Japan Cell and Gene Therapy Market - Competitive Landscape

11 Profiles of Key Players

12 Japan Cell and Gene Therapy Market - Industry Analysis

13 Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â